upregulation. 11 Noxa induction was suggested to be transcriptionally regulated in melanoma cells. 9 Although the mechanisms controlling Noxa gene expression are not fully defined (see Smit et al. 7 for discussion), they appear to be p53-independent in malignant B-cells. 9,10 The protein Noxa induced by either bortezomib or histone deacetylase inhibitors was actually found to bind Mcl-1 in CLL cells. 7, 11 Thus, as Noxa is known to displace Mcl-1/Bak interaction, its upregulation could be a major mechanism by which hyperforin triggers the mitochondrial pathway of caspase activation in CLL cells. Indeed, only marginal effects of the phloroglucinol on Mcl-1 or Bcl-2 were detected here; in addition, Mcl-1 cleavage seems rather a secondary mechanism inasmuch as it was previously found to be caspase-dependent. 4 Our observation that flavopiridol did not stimulate Noxa expression indicates that the flavonoid does not act through the same mechanism as hyperforin or other apoptosis inducers in CLL cells. The strong inhibition of Mcl-1 expression by flavopiridol, as a result of either protein degradation or transcriptional inhibition, may be sufficient to allow a sustained Bak activity, together with convergent downregulation of other antiapoptotic proteins. 4, 8 Moreover, the effects of certain apoptosis inducers could involve proapoptotic Bcl-2 familly members distinct from Noxa and Bak, such as Bak or the BH3-only Puma and Bim. 11 Finally, our results favor the concept that hyperforin and agents having the capacity to induce or mimic Noxa represent a novel attractive therapeutic strategy for CLL, as recently suggested. 12 Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most commonly diagnosed subtypes of non-Hodgkin's lymphoma (NHL) in the United States. 1 Both diseases show variable progression, and identifying prognostic markers applicable in a clinical setting could greatly improve patient management. Established adverse prognostic factors in DLBCL as delineated in the International Prognostic Factor Index (IPI) include older age, higher stage, poor performance score, extranodal involvement and above normal lactate dehydrogenase. For FL, adverse prognostic factors are combined in the Follicular Lymphoma International Prognostic Index and include older age, higher stage, lower hemoglobin level, more nodal areas and above normal lactate dehydrogenase. As both IPI and Follicular Lymphoma International Prognostic Index predict risk incompletely, it is thought that molecular characteristics of the tumor and its microenvironment may improve predicting DLBCL and FL survival. Notably, recent gene expression studies suggest a molecular profile of DLBCL with poorer survival. 2 New prognostic markers for FL have also been suggested, 3 but none have yet been translated to the clinical setting. Evaluating host germline genetic variability offers another promising approach for refining prognosis of DLBCL and FL.
DNA repair and one-carbon metabolism pathways have important functions in maintaining DNA and chromosomal integrity. Briefly, chromosomal translocations, a hallmark of NHL, result from V(D)J recombination or persistent unrepaired DNA double-strand breakage. The ability of a host to repair DNA damage reflects mutations and variations in a large suite of genes that affect non-homologous end joining, homologous recombinational repair, nucleotide-excision repair, base-excision repair and direct damage reversal. DNA damage can also result indirectly when one-carbon metabolism is disrupted from nutrient deficiency (for example, folate and methionine) or from genetic variation in one-carbon metabolism genes. Disruptions within one-carbon metabolism have been linked to insufficient DNA synthesis/repair and subsequent aberrant gene expression.
We hypothesized that DNA repair and one-carbon metabolism pathways may be related to NHL survival by affecting the host's sensitivity to DNA damage and ability to repair DNA damage that results either in response to treatment (for example, radiation) or interaction with treatment (for example, chemotherapy). Here, we evaluated the association between 39 genetic variations among 19 DNA repair genes and 27 singlenucleotide polymorphisms (SNPs) in 17 one-carbon metabolism genes (Table 1) as related to overall survival (for example, risk of dying) from DLBCL and FL, according to those SNPs. Our evaluation was based on population-based cases recruited as part of a large epidemiological population-based case-control study of NHL in the United States (NCI-SEER NHL case-control study).
Full details on this prognosis study have been described earlier. 4 Briefly, histologically confirmed NHL patients aged 20-74 years in four Surveillance, Epidemiology, and End Results (SEER) cancer registries (Detroit; Washington; Iowa; Los Angeles) were enrolled from July 1998 through June 2000. Histology was coded initially according to the International Classification of Diseases-Oncology, second edition, 5 and later updated to the third edition by each registry. For the present analysis, we included the 215 cases of DLBCL and 192 cases of FL with DNA extracted from blood. Follow-up of cases for overall survival was conducted. Date of diagnosis, histology, stage, presence of B symptoms, first course of therapy, date of last follow-up and vital status were derived from registry databases at each study site in the spring of 2005. Data on first course of therapy included use of single-or multiagent chemotherapy, radiation, other therapies exclusive of chemotherapy and/or radiation, and no therapy (observation); information on individual agents and doses was not available. Age, sex, race, Hispanic ethnicity and education level were derived from patient interviews as part of the casecontrol study. Written informed consent was provided by all participants.
The median age at diagnosis for both DLBCL and FL patients was 57 years (range, 20-74). Male patients comprised 54 and 51% of DLBCL and FL, respectively. Ninety-one percentage of DLBCL and FL patients identified themselves as non-Hispanic Caucasians. Fifty-nine percentage of DLBCL and 40% of FL patients had advanced stage disease. Forty percentage of DLBCL and 20% of FL patients had B symptoms. Chemotherapy-based regimen was the most common initial therapy, followed by observation and radiation only. With a median follow-up of 57 months (range, 27-78 months), 50 (23%) DLBCL and 40 (21%) FL patients died.
Details on genotyping have been published earlier; SNPs were previously selected based on prior functional data or expected functional consequences. 6, 7 All genotyping was conducted at the National Cancer Institute Core Genotyping Facility using the Taqman or EPOCH platforms (http://cgf.nci. nih.gov). Sequence data and assay conditions are provided at http://snp500cancer.nci.nih.gov. 8 We used Cox proportional hazards regression (Cox) to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the association of each individual genotype with overall survival, adjusting for age, clinical and demographic factors. Age was modeled according to the standard IPI score as o60 versus 60 þ years. A clinical and demographic risk score was created using a linear combination of the clinical and demographic variables and their multivariable Cox model parameter estimates. The clinical variables used in the risk score included stage (local, regional, distant and missing), presence of B symptoms (no, yes and missing) and type of initial therapy (chemotherapy þ radiation; chemotherapy þ other therapy; radiation only; all other or missing therapy); demographic variables included sex, race (white, other), study center (Detroit, Iowa, Los Angeles, Seattle) and education (o12, 12-15, 16 þ years).
We identified polymorphisms in four DNA repair genes associated with DLBCL survival. Specifically, after adjusting for demographic and clinical variables, SNPs in BRCA1 (rs16942; We identified polymorphisms in three one-carbon metabolism genes associated with DLBCL overall survival. After adjusting for demographic and clinical variables, SNPs in SHMT1 (rs1979276; HR CT/TT ¼ 2.47, 1.31-4.67), BHMT (rs585800; HR AT/TT ¼ 2.02, 1.16-3.54) and TCN1 (rs526934; HR TT ¼ 1.86, 1.04-3.33) were associated with DLBCL survival. In FL, FTHFD (rs1127717) AG/ GG, MTHFR (rs1801131) AC/CC and GGH (rs719235) GT/TT genotypes were associated with overall survival with HRs of 1.99 (95% CI ¼ 1.07-3.7), 2.00 (95% CI ¼ 1.04-3.84) and 2.49 (95% CI ¼ 1.21-5.14), respectively.
We evaluated all possible SNP combinations, summing the number of deleterious genotypes in each multi-SNP combination, and fitting a Cox model adjusting for age and the clinical and demographic risk scores (demographic and clinical risk score was categorized into tertiles, with values of 0-2 (low-tohigh risk)). The models were stratified by the number of SNPs included in the SNP score variable (that is, one SNP, two SNPs,y) and ranked by likelihood. We ran 1000 bootstrap stepwise selection Cox models (adjusting for age, clinical and demographic risk scores) using the selected SNPs and calculated the percentage of models that each SNP was included. We plotted the likelihood to determine the number of SNPs where the reduction in the likelihood became marginal. In parallel, we used results from the bootstrap analysis and from the best-fitting multi-SNP risk score model to develop a final multi-SNP risk score.
We assessed the association of each multi-SNP risk score with overall survival using Kaplan-Meier curves, Cox proportional hazards models and time-dependent receiver-operator characteristics methodology for censored data. We also developed a single risk score that combined the number of deleterious genotypes from the multi-SNP models (0-n) with a combined clinical and demographic risk score (0-2) to create a single-SNP and clinical/demographic risk score (0-n).
We selected a three-SNP model for DLBCL that included BRCA1 (rs16942), XRCC4 (rs1056503) and ERCC2 (rs13181). The reduction in the likelihood became marginal after three SNPs and the three selected comprised the best-fitting multi-SNP score model. The number of deleterious genotypes (as previously defined by the single-SNP results) was summed from these three SNPs (0-3), and this score was strongly associated with survival in both univariate (P ¼ 0.0002) and multivariate (P ¼ 0.0001) analyses. To demonstrate the independent effect of genotype on NHL overall survival, Figure 1a demonstrates that there was a clear gradient in risk (Figure 1a ) (HR ¼ 2.27, 95% CI ¼ 1.57-3.27) for each additional deleterious genotype in the multivariate model, adjusted for demographic and clinical variables. Our combined score of deleterious genotypes (0-3) with the clinical and demographic risk score (0-2) into a single summary SNP and clinical risk score (0-5) was further strongly associated with survival (P ¼ 1.3 Â 10 À7 ). Again, a clear gradient in DLBLC mortality risk was evident ( Figure 1b ) (HR ¼ 2.23, 95% CI ¼ 1.69-2.95). We note that P-values for Kaplan-Meier curves as shown in Figure 1 are also statistically significant.
Among one-carbon metabolism genes, we also selected a three-SNP model for DLBCL that included BHMT (rs585800), SHMT1 (rs1979276) and TCN1 (rs526934). The summary score (0-3) was strongly associated with survival in both univariate (P ¼ 0.0002) and multivariate analyses (P ¼ 1.7 Â 10 À5 ). There was a gradient in risk (Figure 2a ) with each additional deleterious genotype (HR ¼ 2.55, 95% CI ¼ 1.74-3.76) in the multivariate model. Our score of deleterious genotypes (0-3) and clinical and demographic risk score (0-2) combined into a single summary SNP and clinical risk score (0-5) was further strongly associated with survival (P ¼ 2.1 Â 10 À9 ). Risk of dying from DLBCL also increased with severity of score (HR ¼ 2.44, (95% CI ¼ 1.82-3.29), P ¼ 2.1 Â 10 À9 ) (Figure 2b) .
We also selected three one-carbon metabolism SNPs for FL: MTHFR (rs1801131), FTHFD (rs1127717) and GGH (rs719235). There was a gradient in mortality risk (Figure 2c ) with a 2.14-fold increased risk of dying from FL with each additional deleterious genotype (95% CI Letters to the Editor model (P ¼ 0.0002). Our summary SNP and clinical risk score (0-5) was further strongly associated with survival (P ¼ 1.9 Â 10 À6 ). For each severity in score (Figure 2d ), there was a 2.06-fold increase in risk of dying from FL (95% CI ¼ 1.55-2.73). We conducted a time-dependent receiver-operator characteristics analysis for censored data to measure the prognostic capacity of our survival model based on the clinical and demographic risk score with and without genotype information, as measured by the area under the curve (AUC). For DLBCL survival, the DNA repair and one-carbon metabolism gene models' combined risk scores had a concordance index (AUC) at 5 years of follow-up of 0.73 (Figure 3a) . For FL survival, the one-carbon metabolism gene model combined risk score had an AUC at 5 years of follow-up of 0.72 (Figure 3b ). Combined DNA repair and one-carbon metabolism gene AUC for DLBCL was 0.78 (Figure 3a) . These AUCs approach the predictive range needed for clinically useful tests.
Finally, to ensure the validity of our multi-SNP model results, we also conducted a permutation analysis to evaluate the statistical significance of our results compared with chance. Specifically, we applied our model-building approach to each of the 200 permuted data sets; the significance of the best model for each data set was recorded. For DLBCL, both our three-SNP models for DNA repair genes and one-carbon metabolism genes from the true data outperformed the best model generated from 495% of the permuted random data sets, suggesting that our multi-SNP model has a high level of significance. Our three-SNP model for FL and one-carbon metabolism genes from the true data performed better than the best model generated from 490% of the permuted random data sets.
The potential relevance of DNA repair genes in cancer survival has been reported in other tumors. The ERRC2 K751Q and XRCC2 R188H polymorphisms have both been reported to be associated with autologous stem cell transplantation failure in multiple myeloma patients. The XRCC2 R188H polymorphism was also associated with breast cancer and pancreatic cancer survival. It is interesting to note that genes we have identified earlier, as relevant for etiology, 6 were not predictive for survival, potentially suggesting distinct functions for these gene variations in etiology compared with survival. Although we infer based on our results that homologous and nucleotideexcision repair may be relevant for DLBCL survival, we cannot exclude the potential relevance of other DNA repair pathways as we did not comprehensively evaluate all DNA repair genes and their variations. Of the one-carbon metabolism genes identified as relevant for DLBCL or follicular overall survival, no other reports have implicated BHMT, TCN1, FTHFD or SHMT with any cancer, but numerous reports associate MTHFR polymorphisms with survival in NHL and cancers of the breast, colon, bladder and stomach.
An important strength of our study was the population-based ascertainment of newly diagnosed cases, making our results relevant for community-based treatment programs. Study limitations include the lack of detailed data on prognostic factors or treatment. Although our clinical and demographic risk score predicted survival with AUCs for DLBCL and FL comparable with their respective IPIs, 4 future studies that incorporate Ann Arbor and IPI classifications will be important for translation of confirmed gene associations to clinical applications or any risk-prediction model. In summary, we show that host genetic variations in DNA repair and one-carbon metabolism gene polymorphisms can stratify risk for overall survival in DLBCL and FL after accounting for demographic and clinical factors. A detailed evaluation of genes in these two pathways and their interaction with dietary nutrients and specific therapeutic agents may be informative. Our results require replication in an independent population and further evaluation among cases treated with rituximab. Understanding the functional relevance of confirmed gene variations and their influence on therapy response should also be pursued. Epidemiological information on chronic myeloproliferative disorders (CMPDs), notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukemia (CML), is rare. 1 Reports from population-based registries 2-5 show a high variability of crude and standardized incidences rates of 0.6-2.0 for CML and the other CMP entities. Few data are available on the proportion of patients recruited to clinical trials and on the representativity of study patients for the whole patient population. The median age of CML patients differs between cancer registries and clinical trials by 10-20 years. A Scottish study 6 indicates that only 52% of CML patients were enrolled in clinical trials. We, therefore, sought to conduct an evaluation (i) to determine population-based age-and gender-specific incidences of CML and other CMPDs (polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and myelomonocytic leukemia (CMML)) in a representative region of Germany, and (ii) to compare CML patients participating or not participating in clinical studies.
The study was carried out in a predefined area in Southwest Germany with 9.2 million inhabitants between January 1998 and December 2000. The area included the federal states of Baden-Wü rttemberg, Hessen, Rhineland-Palatinate and Saarland where demographics were similar. The borders to France, Luxembourg and Belgium in the South and West and geography (mountains) in the North and East limited patient fluctuation. All CMPD patients had the same access to medical treatment. If patients residing in the target area visited centers outside the reporting area, they were included in the study. Population data were obtained from the authorities. All 37 hematooncological centers including five university hospitals, 11 larger community hospitals and 21 specialty practices registered by the authorities were invited for cooperation. In addition, the 1792 hospitals and practices with focus internal medicine or pediatrics were contacted assuming that some of them also would treat CMPD cases. If a center had a newly diagnosed CML patient, resident in the study region, a completed standardized prospective questionnaire with pseudonymized data for sociodemographic and clinical baseline characteristics at the time of diagnosis was requested. For PV, ET, PMF, unclassified CMPD (UCMPD) and CMML, age, gender, area of residence and date of diagnosis were recorded. The definitions of diagnoses followed the World health organization criteria. BCR-ABL analysis by multiplex PCR was offered to confirm diagnosis of CML and to differentiate between CML and BCR-ABL-negative CMPD in atypical cases. As a reminder, the participating centers received follow-up letters and phone calls by the study center every 3 months.
All large hematooncological centers of the area (n ¼ 16) participated and reported 408 (46.5%) CMPD cases. Twelve of twenty-one hematooncological specialty practices (57.1%) reported 139 (15.8%) additional patients. The remaining patients were mostly recruited by practising internists (n ¼ 225, 25.7%) and smaller hospitals (n ¼ 99, 11.3%). Six cases (0.7%) were reported from 20 pediatric hospitals. The 877 reported CMPD cases (median age at the time of diagnosis, 67.9 years; range, 6. . Nine patients were younger than 20 years at diagnosis. A total of 460 (52.5%) of the 877 CMPD cases were men. The male-to-female ratio for CML, PV, PMF and CMML was 1.66, 1.10, 1.52 and 2.14, respectively, for ET 0.70. The overall crude annual incidence of CMPD cases was
